DermaPACE: Phase III data

Data from a total of 336 patients in a pair of double-blind, international Phase III trials showed that dermaPACE plus conventional therapy missed the primary endpoint of improving complete wound closure rate from baseline at 12 weeks vs. sham control plus conventional therapy (22.7%

Read the full 443 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE